english.prescrire.org > Spotlight > 100 most recent > GLP-1 agonists: depression, suicidal thoughts or behaviour (continued)

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

GLP-1 agonists: depression, suicidal thoughts or behaviour (continued)

 Adverse Effects  In late 2023, based on our analysis of the available clinical evaluation data and pharmacovigilance data, it appeared prudent to consider that GLP-1 agonists, such as semaglutide and liraglutide, carry a risk of depression, suicidal thoughts, suicide attempts or suicide. What more is known about these risks as of 2025?
Full article available (4 pages) for download by subscribers

 ©Prescrire 1 June 2025

Source: "GLP-1 agonists: depression, suicidal thoughts or behaviour (continued)" Prescrire Int 2025; 34 (271): 158-161. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"GLP-1 agonists: depression,
suicidal thoughts or behaviour"
Prescrire Int 2024;
33 (258): 103-105.
Subscribers only

"Semaglutide in secondary
cardiovascular prevention
in overweight or obese patients"
Prescrire Int 2024;
33 (260): 157-158.
Subscribers only